Particle.news

Download on the App Store

Bupa Launches Immersive Genome Display in London With DNA Medication Test Rollout

The exhibit promotes personalised care by pairing the test launch with company findings on drug sensitivity plus genetic risk.

Overview

  • The Outernet’s Now Trending venue in London now features a public genome scroll of 3.2 billion characters, on display through October 1.
  • Bupa tied the reveal to the rollout of its Medication Check DNA Health Test, designed to cut trial-and-error prescribing using pharmacogenomic insights.
  • A company-run whole genome sequencing pilot of 2,200 adults reported that 99% carried variants affecting sensitivity to common medicines.
  • Pilot results cited risk signals for 36 preventable conditions, with 91% showing some combined genetic–lifestyle risk, 73% with multiple risk variants, and 49% as carriers for inherited conditions.
  • A Bupa-commissioned OnePoll survey reported low genomic literacy, with 67% unaware of what a genome is, 26% avoiding routine screenings, and 37% admitting to ignoring health issues.